Gardasil
Showing 26 - 50 of 173
Human Papillomavirus Infections Trial in Montréal, Québec (Quadrivalent HPV vaccine)
Completed
- Human Papillomavirus Infections
- Quadrivalent HPV vaccine
-
Montréal, Quebec, Canada
- +1 more
Apr 21, 2022
HIV Trial in Pathum Wan (GINI)
Active, not recruiting
- HIV
- GINI
-
Pathum Wan, Bangkok, ThailandThe Thai Red Cross AIDS Research Centre
Jul 8, 2021
Meningitis, Meningococcal Meningitis, Meningococcal Infections Trial in Puerto Rico, United States (Meningococcal Polysaccharide
Completed
- Meningitis
- +2 more
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
- +3 more
-
Birmingham, Alabama
- +35 more
Mar 24, 2022
Human Papillomavirus Infection Trial in Kunming (Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus
Active, not recruiting
- Human Papillomavirus Infection
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
- GARDASIL® 9
-
Kunming, Yunnan, ChinaYunnan Center for Disease Prevention and Control
Dec 23, 2022
Cervical Intraepithelial Neoplasia Trial (HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation)
Not yet recruiting
- Cervical Intraepithelial Neoplasia
- HPV9 High formulation
- +3 more
- (no location specified)
Aug 10, 2022
Interventional, Prevention, Randomized Trial in Nanjing (SCT1000, Gardasil®9, Gardasil®)
Recruiting
- Interventional
- +2 more
- SCT1000
- +3 more
-
Nanjing, Jiangsu, ChinaGuanyun Country CDC
Oct 21, 2021
High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion Trial in Birmingham, Seattle
Terminated
- High Grade Anal Canal Intraepithelial Neoplasia
- High Grade Vulvar Squamous Intraepithelial Lesion
- Laboratory Biomarker Analysis
- +3 more
-
Birmingham, Alabama
- +1 more
Jan 24, 2023
HPV Infection, HPV Vaccination Trial in Thika (Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine)
Recruiting
- HPV Infection
- HPV Vaccination
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
-
Thika, Kiambu, KenyaPhrd-Ccr-Kemri
Jun 22, 2022
Genital Warts Trial in Guang'an, Mianyang (9vHPV vaccine)
Recruiting
- Genital Warts
- 9vHPV vaccine
-
Guang'an, Sichuan, China
- +1 more
May 11, 2022
HPV Trial in Atlanta (Gardasil, Lidocaine injections)
Recruiting
- HPV
- Gardasil
- Lidocaine injections
-
Atlanta, Georgia
- +1 more
Dec 21, 2021
HPV Infection Vaccine Safety SCT1000 Trial in Nanjing (SCT1000, Gardasil®9, )
Recruiting
- HPV Infection Vaccine Safety SCT1000
- SCT1000
- +3 more
-
Nanjing, Jiangsu, ChinaGuanyun Country CDC
Sep 14, 2021
HPV Vaccine in Postpartum Women
Withdrawn
- HPV Infection
- HPV 9-valent Vaccine, Recombinant
- (no location specified)
Jun 30, 2021
Human Papillomavirus Infection Trial in United States (Laboratory Biomarker Analysis, Questionnaire Administration, Recombinant
Active, not recruiting
- Human Papillomavirus Infection
- Laboratory Biomarker Analysis
- +2 more
-
Birmingham, Alabama
- +5 more
Jan 26, 2023
Papillomavirus Vaccines Trial in Norfolk (Gardasil-9)
Recruiting
- Papillomavirus Vaccines
- Gardasil-9
-
Norfolk, VirginiaEVMS Otolaryngology
Aug 17, 2021
Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV Trial
Recruiting
- Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III)
- +3 more
- Nonavalent HPV vaccine (9vHPV/Gardasil-9™).
-
L'Hospitalet De Llobregat, Catalunya, SpainGynaecology Unit, Bellvitge University Hospital (HUB)
Jan 24, 2023
Human Papilloma Virus, Hiv, Organ Transplants Trial in Leuven (9-valent HPV vaccine)
Completed
- Human Papilloma Virus
- +2 more
- 9-valent HPV vaccine
-
Leuven, BelgiumUZ Leuven
Nov 17, 2020
Cancer Survivor, Prevention of Human Papillomavirus Infection Trial in United States (quadrivalent human papillomavirus (types
Completed
- Cancer Survivor
- Prevention of Human Papillomavirus Infection
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)
- +3 more
-
Birmingham, Alabama
- +4 more
Oct 7, 2021
Papilloma Viral Infection Trial in Saint-Pierre (Gardasil 9, 9-Valent Intramuscular Suspension)
Completed
- Papilloma Viral Infection
- Gardasil 9, 9-Valent Intramuscular Suspension
-
Saint-Pierre, FranceCentre Hospitalier Universitaire de la Réunion
Mar 1, 2022
Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus Trial in Vancouver, Ottawa, Toronto (9-valent HPV
Not yet recruiting
- Anal Intraepithelial Neoplasia
- +2 more
- 9-valent HPV vaccination
-
Vancouver, British Columbia, Canada
- +3 more
Jun 9, 2022
HPV Infection, HPV-Related Cervical Carcinoma Trial in Liuzhou (Biological/Vaccine: 11-valent recombinant human papilloma virus
Active, not recruiting
- HPV Infection
- HPV-Related Cervical Carcinoma
- Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- 9-valent HPV vaccine(Gardasil 9)
-
Liuzhou, Guangxi, ChinaLiucheng Center for Disease Control and Prevention
Feb 13, 2022
HPV Infection, Hiv, HPV Vaccine Trial in Swaziland (Gardasil ® 9)
Recruiting
- HPV Infection
- +2 more
- Gardasil ® 9
-
Bulembu, Swaziland
- +7 more
May 16, 2022
Cancer of Cervix Trial in Cuernavaca (Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine], Two
Completed
- Cancer of Cervix
- Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine]
- +3 more
-
Cuernavaca, Morelos, MexicoInstituto Nacional de Salud Publica
Nov 24, 2021
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent Trial run by the NCI (Gardasil, Survey)
Completed
- Human Immunodeficiency Virus
- +3 more
- Gardasil
- Survey
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Jan 26, 2022
HPV Infection, CIN 2/3, Cervical Cancer Trial in Stockholm (Gardasil9)
Recruiting
- HPV Infection
- +2 more
- Gardasil9
-
Stockholm, SwedenCancer prevention, screening, and counseling unit, Regional Canc
Sep 9, 2021
Cervical Cancer Trial in Gyeonggi-do (NBP615, Gardasil)
Completed
- Cervical Cancer
- NBP615
- Gardasil
-
Gyeonggi-do, Seongnam-si, Korea, Republic ofSK Bioscience
Sep 24, 2021